TY - JOUR
T1 - Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy
AU - Buemi, Michele
AU - Allegra, Alessandro
AU - Corica, Francesco
AU - Aloisi, Carmela
AU - Giacobbe, MariaStella
AU - Pettinato, Giuseppina
AU - Corsonello, Andrea
AU - Senatore, Massimino
AU - Frisina, Nicola
PY - 2000
Y1 - 2000
N2 - 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are established drugs for the treatment of hypercholesterolemia, but several studies have shown that benefits obtained with these drugs are not causally related only to regression of cholesterol lowering: Moreover, in experimental models of progressive renal disease, statins have reduced the extent of glomerulosclerosis. This study evaluated the antiproteinuric effect of a daily dose of 40 mg fluvastatin for 6 months in moderately proteinuric patients with immunoglobulin A nephropathy, stable renal function, and no indicators of poor long-term prognosis. The effects of therapy were evaluated on the basis of 24-hour proteinuria (total proteinuria and albuminuria), albuminemia, creatinine clearance, cholesterols and triglyceride values. Renal function remained stable in all patients. A significant decrease in proteinuria was observed after 6 months of therapy and persisted for all the observations. An increase in serum albumin was observed after 6 months of therapy. This study suggests that there is an antiproteinuric effect of HMG- CoA reductase inhibitors in moderately proteinuric patients with immunoglobulin A nephropathy.
AB - 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are established drugs for the treatment of hypercholesterolemia, but several studies have shown that benefits obtained with these drugs are not causally related only to regression of cholesterol lowering: Moreover, in experimental models of progressive renal disease, statins have reduced the extent of glomerulosclerosis. This study evaluated the antiproteinuric effect of a daily dose of 40 mg fluvastatin for 6 months in moderately proteinuric patients with immunoglobulin A nephropathy, stable renal function, and no indicators of poor long-term prognosis. The effects of therapy were evaluated on the basis of 24-hour proteinuria (total proteinuria and albuminuria), albuminemia, creatinine clearance, cholesterols and triglyceride values. Renal function remained stable in all patients. A significant decrease in proteinuria was observed after 6 months of therapy and persisted for all the observations. An increase in serum albumin was observed after 6 months of therapy. This study suggests that there is an antiproteinuric effect of HMG- CoA reductase inhibitors in moderately proteinuric patients with immunoglobulin A nephropathy.
UR - http://www.scopus.com/inward/record.url?scp=0034069293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034069293&partnerID=8YFLogxK
M3 - Article
C2 - 10801253
AN - SCOPUS:0034069293
VL - 67
SP - 427
EP - 431
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 4
ER -